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P-Sizer for Thrombectomy in Acute Myocardial
nfarction Improves ST-Segment Resolution
esults of the X-Sizer in AMI for Negligible
mbolization and Optimal ST Resolution (X AMINE ST) Trial
hierry Lefèvre, MD,* Eulegio Garcia, MD,† Bernhard Reimers, MD,‡ Iréne Lang, MD,§
arlo di Mario, MD, Antonio Colombo, MD,¶ Franz-Joseph Neumann, MD,#
ariano Valdés Chavarri, MD,** Philippe Brunel, MD,†† Eberhart Grube, MD,‡‡ Martin Thomas, MD,§§
ernard Glatt, MD, Joseph Ludwig, MD,¶¶ on behalf of the X AMINE ST Investigators
assy, Nantes, and Saint-Denis, France; Madrid and Murica, Spain; Mirano and Milano, Italy; Vienna, Austria;
ad Krozingen, Siegburg, and Erlangen, Germany; and London, United Kingdom
OBJECTIVES We sought to compare, in a prospective randomized multicenter study, the effect of adjunctive
thrombectomy using X-Sizer (eV3, White Bear Lake, Minnesota) before percutaneous
coronary intervention (PCI) versus conventional PCI in patients with acute myocardial
infarction (AMI) for 12 h and Thrombolysis In Myocardial Infarction (TIMI) flow grade
0 to 1. The primary end point was the magnitude of ST-segment resolution after PCI.
BACKGROUND Despite a high rate of TIMI flow grade 3 achieved by PCI in patients with AMI, myocardial
reperfusion remains relatively low. Distal embolization of thrombotic materials may play a
major role in this setting.
METHODS We conducted a prospective, randomized, multicenter study in patients with AMI12 h and
initial TIMI flow grade 0 to 1 who were treated with primary PCI. The magnitude of
ST-segment resolution 1 h after PCI was the primary end point.
RESULTS A total of 201 patients were included. Treatment groups were comparable by age (61  13
years), diabetes (22%), previous MI (8%), anterior MI (52%), onset-to-angiogram (258 173
min), and glycoprotein IIb/IIIa inhibitor use (59%). The magnitude of ST-segment
resolution was greater in the X-Sizer group compared with the conventional group (7.5 vs. 4.9
mm, respectively; p 0.033) as ST-segment resolution50% (68% vs. 53%; p 0.037). The
occurrence of distal embolization was reduced (2% vs. 10%; p  0.033) and TIMI flow grade
3 was obtained in 96% vs. 89%, respectively (p 0.105). Myocardial blush grade 3 was similar
(30% vs. 31%; p  NS). Six-month clinical outcome was comparable (death, 6% vs. 4% and
major adverse cardiac and cerebral events, 13% vs. 13%, respectively). By multivariate analysis,
independent predictors of ST-segment resolution50% were: younger age, non-anterior MI,
use of the X-Sizer, and a short time interval from symptom onset.
CONCLUSIONS Reducing thrombus burden with X-Sizer before stenting leads to better myocardial reperfu-
sion, as illustrated by a reduced risk of distal embolization and better ST-segment
resolution. (J Am Coll Cardiol 2005;46:246–52) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.031Cardiology Foundation
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tercutaneous coronary intervention (PCI) and stenting
urrently are considered the gold standard treatment (1) in
atients with acute myocardial infarction (AMI). This
reatment has been shown to increase the rate of acute
hrombolysis In Myocardial Infarction (TIMI) flow grade
of the infarct-related artery (IRA) (2,3), which is corre-
ated with better mid- and long-term outcomes. However,
IMI flow grade 3 is only the tip of the iceberg, and a
iscrepancy between vessel patency and rescue of the jeop-
rdized myocardium after interventional or pharmacologic
From the *Institut Cardiovasculaire Paris Sud, Massy, France; †Hospital Gregorio
arañon, Madrid, Spain; ‡Ospedale Civile, Mirano, Italy; §AKH, Vienna, Austria;
Ospedale San Raffaele, Milano, Italy; ¶Centro Cuore Columbus, Milano, Italy;
Herzzentrum, Bad Krozingen, Germany; **Hospital Universitario ‘Virgen de la
rrixaca’, Murcia, Spain; ††Clinique Saint Henri, Nantes, France; ‡‡Heart Center
ospital, Siegburg, Germany; §§King’s College Hospital, London, United Kingdom;
Centre Cardiologique du Nord, Saint-Denis, France; and ¶¶Klinikum der Uni,
rlangen, Germany. This study was supported by eV3.d
Manuscript received November 18, 2004; revised manuscript received March 8,
005, accepted April 14, 2005.reatment of AMI has been documented in at least one-
hird of patients (4–8). This discrepancy between angio-
raphic epicardial flow and myocardial tissue reperfusion is
ultifactorial (9–13). However, the main issue is probably
he occurrence of distal embolization of plaque and throm-
us debris, either spontaneously or induced by percutaneous
ntervention, which may lead to obstruction in distal coro-
ary branches or arterioles, limiting the efficacy and the
xtent of myocardial tissue reperfusion. In a recent work,
enriques et al. (14) showed that the occurrence of angio-
raphically visible distal embolization during primary PCI was
bserved in 15% of cases and that it was significantly associated
ith a high rate of death at five-year follow-up compared with
atients who had no distal embolization. New mechanical
evices to remove thrombus and to prevent embolization of
hrombus and plaque during PCI have become available
15–18), but few randomized studies have been performed in
he setting of primary angioplasty (19,20). The present ran-
omized study was designed to evaluate the effects of mechan-
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July 19, 2005:246–52 Results of the X AMINE ST Trialcal thrombus removal on myocardial tissue reperfusion in
atients undergoing primary PCI. Because the mortality rate
fter primary PCI has become relatively low, we decided to use
T-segment resolution as a surrogate end point, given that it is
ne of the most sensitive and reliable markers of myocardial
eperfusion (21) and has proved to be highly correlated with
ong-term outcome (22).
ETHODS
tudy population. Patients suffering an AMI who were
menable to PCI were included in 14 European centers with
revious experience in the use of the X-Sizer device (X-
izer catheter system; eV3, White Bear Lake, Minnesota).
he inclusion criterion was AMI for 12 h (i.e., evidence
f ischemic chest pain for 30 min and new ST-segment
levation for 2 mm in two or more contiguous electrocar-
iographic [ECG] leads, de novo lesion, single-vessel treat-
ent in a native vessel 2.5 mm in diameter and occluded,
hrombus-containing, TIMI flow grade 0 to 1 infarct-
elated artery). Main exclusion criteria were previous PCI in
RA, rescue PCI, Killip class3, left or right bundle branch
lock, IRA with excessive proximal tortuosity or severe
alcification, left ventricular ejection fraction 30%, con-
raindication to emergency coronary artery bypass grafting,
nd current participation in another study protocol.
After providing informed consent, patients fulfilling the
nclusion and exclusion criteria were assigned randomly 1:1
o intracoronary thrombectomy, followed by PCI and stent-
ng, or to PCI, excluding anything but balloon angioplasty
nd stent. Glycoprotein (GP) IIb/IIIa inhibitors were used
ccording to the operator’s judgment.
rocedure and device description. Thrombectomy was
erformed using the X-Sizer catheter system. This device is
two-lumen over-the-wire system (available diameters 1.5
nd 2.0 mm) with a helical shape cutter at its distal tip. The
utter rotates at 2,100 rpm driven by a hand-held battery
otor unit. One catheter lumen is connected to a 250-ml
acuum bottle, and aspirated debris is collected in an in-line
lter. Two or more passages across the lesion from proximal
o distal were performed by slowly advancing the activated
atheter. Subsequently, additional balloon angioplasty or
Abbreviations and Acronyms
AMI  acute myocardial infarction
CI  confidence interval
cTFC  corrected TIMI frame count
ECG  electrocardiogram/electrocardiographic
GP  glycoprotein
IRA  infarct-related artery
MACCE  major adverse cardiac and cerebral events
OR  odds ratio
PCI  percutaneous coronary intervention
TIMI  Thrombolysis In Myocardial Infarctionoronary stenting was performed. Before the intervention, pll patients received aspirin. Heparin (70 U/kg) was given to
aintain an activated clotting time of 250 s.
ngiographic analysis. The coronary angiograms were
nalyzed by an independent core laboratory (Dr. Glatt,
orisis, St. Denis, France) that was blinded to other data. In
ompliance with the protocol, the X-Sizer was systemati-
ally filmed with the purpose of measuring its effect on
IMI flow grade and thrombus burden and was, therefore,
isible by the operator. Quantitative coronary analysis was
erformed before and after the procedure using the quan-
ification system CMS-View (version 4.0; MEDIS, Leiden,
he Netherlands). Angiographic TIMI flow grade was
stimated visually, as previously described (23). The cor-
ected TIMI frame count (cTFC) was measured with a
rame counter on a digital film viewer analyzing the number
f cine frames required for contrast to first reach a stan-
ardized distal coronary landmark (24). Recorded cine film
peeds were 12.5, or 25 frames/s. All the results were
orrected in 33 frames/s. In the presence of an occluded
essel (visual TIMI flow grade 0 to 1), cTFC was set to a
alue of 100 (25).
The incidence of distal embolization during the proce-
ure also was assessed as previously described by Henriques
t al. (14), as well as the occurrence of slow flow (TIMI flow
rade decreasing from 3 to 2 during the procedure) or no
eflow (TIMI flow grade decreasing from 2 or 3 to 0 or 1
uring the procedure). The composite angiographic end
oint of slow-flow, no reflow, or distal embolization also
as assessed. Thrombus burden at the lesion site was graded
rom 0 to 5 using the TIMI thrombus score (26). Partial
hrombus removal after X-Sizer was defined by a reduction
y at least one grade but remaining thrombus and complete
emoval by a reduction of more than one grade with no
esidual thrombus. All data were determined at baseline,
fter guidewire positioning, after thrombectomy, and at the
nd of the procedure. Myocardial blush grade was assessed
efore and after the procedure by a different independent
ore laboratory, which originally described the technique
Dr. Suryapranata, Zwolle, the Netherlands) (8).
CG analysis. In each patient, a 12-lead ECG was re-
orded at admission, 60 min after the procedure, and at
ischarge. Electrocardiograms were analyzed by Corisis
sing the MPTronic ECG analyzer (MPTronic, Paris,
rance). The algebraic sum of ST-segment elevation and
epression 20 ms from the J-point was assessed as previously
escribed by Claeys et al. (22). Scanned images from
riginal recording ECG were used. The image obtained was
caled on the squaring according to the speed and the
mplitude of recording. For each lead, the baseline was
utomatically determined by the software (determination
ultipoints Iso segment between ST-T and P). For one
RS complex analyzed, the software determines automat-
cally, after manual marking the end of the QRS complex,
he time selected for the measurement of ST-segment
levation. The software identified for each derivation the
oint of intersection corresponding ST-segment and mea-
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Results of the X AMINE ST Trial July 19, 2005:246–52ures the height of ST-segment elevation or depression
xpressed in mV.
tudy end points. The primary end point was the magni-
ude of resolution of the sum of ST-segment before and 1 h
fter the procedure. Secondary end points were: ST-
egment resolution 50%; the occurrence of distal emboli-
ation; the composite angiographic end point of slow flow,
o reflow, and/or distal embolization; cTFC; myocardial
lush score; and the major adverse cardiac and cerebral
vents (MACCE) at one and six months. Safety end points
ere defined as the incidence of procedural and six months
-Sizer–related severe adverse events.
evice performance. To assess the performance of the
evice, the following definitions were used: acute X-Sizer
uccess was defined as successful delivery of the X-Sizer
atheter system to the IRA, achieving a TIMI flow grade
mprovement greater than one grade. Acute procedure
uccess was defined as the achievement of a final diameter
tenosis 30% by quantitative coronary analysis with a final
IMI flow grade 3 and no occurrence of slow-flow, no-
eflow phenomenon, or distal embolization.
tatistical analysis. The number of patients included in
he study was based on the estimation of the sample size
eeded to identify a significant difference for the primary
nd point (i.e., the magnitude of ST-segment resolution)
nd main secondary end point (i.e., the percentage of
atients with ST-segment resolution 50%). Under the
ssumption that the secondary end point is the ratio of
omplete ST-segment resolution and that a ratio of 65%
ould be improved by the X-Sizer catheter to 90%, the
ecessary sample size (based on a two-tailed Fisher exact
est, calculated with SAS, version 8.2; SAS Institute, Cary,
orth Carolina) was calculated to 65 patients in each arm
alpha  0.05, power  90%). Considering potential
ropouts of patients during the study, the sample size in
ach arm was increased to 100 patients. All analyses were
erformed according to the intention-to-treat principle.
ategorical variables are presented as frequency values and
ere compared by using the Fisher exact test. Continuous
ariables are expressed as mean  SD and were compared
y using the Wilcoxon rank sum test. For the primary end
oint, the Student t test and analysis of variance also were
erformed. Repeated measures of continuous variables were
nalyzed by non-parametric repeated measures analysis of
ariance without correction for multiple comparisons be-
ause of their exploratory nature. Multivariate linear regres-
ion analysis was performed to identify independent predic-
ors of ST-segment resolution. This model included age,
nfarct location, diabetes, Killip class, ischemic time, previ-
us myocardial infarction, multivessel disease, use of GP
Ib/IIIa inhibitors, direct stenting, and thrombectomy using
-Sizer. A p  0.05 was interpreted as statistically signif-
cant. Statistical analysis was performed using SAS software.
tudy organization. The Data and Safety Monitoring
oard and the Clinical Events Committee were separate
esignated groups of qualified individuals not involved in ihe study that monitored safety and adjudicated clinical end
oints, respectively. The angiographic committee was in
harge of resolving disagreements between the angiographic
ore laboratory and the study investigators.
ESULTS
f the 201 patients included in the study, 101 patients were
ssigned randomly to the control group and 100 patients to
he X-Sizer group. There were no significant differences in
aseline clinical characteristics between the two groups
Table 1).
rocedural data and angiographic analysis. Procedural
ata are reported in Table 2. The only differences between
oth groups was the procedure duration, which was longer
n the X-Sizer group compared with the control group (54
28 min vs. 45  25 min, respectively; p  0.003) and the
ate of stenting without balloon predilation, which was
igher in the X-Sizer group (60% vs. 34%, respectively; p 
.001). Angiographic results were fully available in 97
atients in the X-Sizer group and 100 in the control group
Table 3). There was a trend for a better TIMI flow grade
t the end of the procedure in the X-Sizer group (2.96 
.20 vs. 2.89 0.31; p 0.070) with a higher rate of TIMI
ow grade 3 (95.9% vs. 89.0%; p  0.105) and a better
TFC (22.6  8.2 frames/s vs. 25.1  15.0 frames/s; p 
.898). Distal embolization was observed less frequently in
he X-Sizer group (2.1% vs. 10%; p  0.033), as was the
omposite angiographic end point of slow flow, no reflow,
r distal embolization (6.0% vs. 19.8%; p  0.006).
hrombectomy results and device safety. The 1.5-mm
-Sizer device was used in 81.2% of cases and the 2-mm
evice in the remaining cases. Acute X-Sizer success was
btained in 87% of cases. Thrombus removal was complete
able 1. Baseline Clinical Characteristics
No
Thrombectomy Thrombectomy
p
Value
atients, n 101 100
ge, yrs 62  11 61  13 NS
emale gender, % 27 24 NS
isk factors, %
Diabetes 18 25 NS
Hypertension 50 54 NS
Dyslipidemia 61 58 NS
Current smoking 51 52 NS
revious MI, % 6 10 NS
MI, kg/m2 27  4 27  5 NS
nterior MI, % 50 54 NS
illip class I, % 19 18 NS
nset-to-angiogram,
min
264  194 251  151 NS
-vessel disease, % 58 61 NS
-vessel disease, % 24 26 NS
-vessel disease, % 18 13 NS
ontinuous data presented as mean SD and are compared using the Wilcoxon rank
um test; categorical data are presented as frequency values and are compared using
he Fisher exact test.
BMI  body mass index; MI  myocardial infarction; NS  not significant.n 38.8% of cases and partial in 58.0%. A TIMI flow grade
2
a
8
s
i
X
v
m
A
f
i
b
t
o
r
p
0
t
w
p
w
s
r
i
2
0
cant; P
ction.
249JACC Vol. 46, No. 2, 2005 Lefèvre et al.
July 19, 2005:246–52 Results of the X AMINE ST Trialor 3 was present before wiring the lesion in 4.1% of cases,
fter wiring the lesion in 20.6%, and after thrombectomy in
8.0%. No case of acute coronary perforation or other
erious device-related adverse event was observed. However,
n one patient with anterior AMI, in which a 1.5-mm
-Sizer device failed to cross the lesion, a coronary arterio-
enous fistula was observed at follow-up, which was treated
edically.
ssessment of myocardial reperfusion. Blush data were
ully available in 92 patients in the X-Sizer group and in 91
n the control group (Table 3). No difference was found
etween either of the groups (Table 3). However, by using
he predefined ECG criteria, a significant difference was
Table 2. Baseline Angiographic Data and Proc
No T
Patients, n
Target vessel, %
LAD
LCX
RCA
Lesion length, mm 13
Reference diameter pre-PCI, mm 3.
TIMI flow grade pre-PCI, % 0.
MLD pre-PCI, mm 0.
Stenosis pre-PCI, % 96
cTFC pre-PCI, 25 frames/s 97
Procedural details
Glycoprotein IIb/IIIa inhibitors, %
Coronary stenting, %
Stenting without predilation, %
Procedural time, min
Number of stents, mean 1.
Stent length, mm 22
Maximum pressure, atm 13
Stent/vessel ratio 1.
Continuous data presented as mean  SD and are compared
as frequency values and are compared using the Fisher exact
cTFC  corrected TIMI frame count; LAD  left ante
artery; MLD  mean luminal diameter; NS  not signifi
coronary artery; TIMI  Thrombolysis In Myocardial Infar
Table 3. Postprocedural Angiographic Data
No T
Patients, n
Reference diameter post-PCI, mm 3
MLD post-PCI (mm) 2
Stenosis final, % 1
TIMI flow grade 2
TIMI flow, % grade 3
cTFC, final 2
Myocardial blush grade (0–3) 2
0–1
2
3
Distal embolization, %
Slow flow, %
No flow, %
Composite angiographic end point, %
Angiographic success, %
Procedural success, %Abbreviations as in Table 2.bserved (Table 4): postprocedural ST-segment elevation
egressed 50% in a significantly higher percentage of
atients treated with thrombectomy (67.8% vs. 52.6%; p 
.037), and the median magnitude of ST-segment resolu-
ion at 1 h after PCI was increased with thrombectomy
hen compared with the control group (7.50 vs. 4.90 mm;
 0.033). By using multiple logistic regression analysis,
e discovered that the independent predictors of ST-
egment resolution 50% were: younger age (with an odds
atio [OR] of 0.73 per 10 years and a 95% confidence
nterval [CI] of 0.56 to 0.95; p 0.021), anterior AMI (OR
.23, 95% CI 1.17 to 4.24; p  0.015), use of X-Sizer (OR
.49, 95% CI 0.26 to 0.94; p  0.031), and shorter time
al Data
bectomy Thrombectomy p Value
100
55
7 NS
37
5.0 12.7  5.0 NS
0.60 3.13  0.62 NS
0.52 0.15  0.46 NS
0.26 0.08  0.27 NS
10.1 97.2  9.0 NS
11.9 98.2  9.5 NS
55 NS
100 NS
60 0.001
25 54  28 0.009
0.65 1.32  0.61 NS
9.9 22.2  12.0 NS
2.6 13.7  2.7 NS
0.45 1.07  0.27 NS
the Wilcoxon rank sum test; categorical data are presented
escending coronary artery; LCX  left circumflex coronary
CI  percutaneous coronary intervention; RCA  right
bectomy Thrombectomy p Value
100
0.48 3.30  0.51 NS
0.53 2.76  0.52 NS
9.7 16.9  9.5 NS
0.31 2.96  0.20 0.070
.0 95.9 0.105
15.0 22.6  8.2 0.898
0.75 2.03  0.81 0.898
.0 24.7
.6 44.1 NS
.4 31.2
.0 2.1 0.033
.9 1.0 0.119
.9 3.0 0.082
.8 6.0 0.006
.0 86.6 0.189
.0 84.5 0.112edur
hrom
101
48
5
43
.7 
10 
18 
10 
.3 
.3 
65
99
34
45 
37 
.7 
.9 
14 
using
test.
rior dhrom
101
.27 
.72 
7.2 
.89 
89
5.1 
.05 
25
44
30
10
5
9
19
79
75
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Results of the X AMINE ST Trial July 19, 2005:246–52nterval from symptom onset to PCI (OR, 0.88 per h, 95%
I 0.79 to 0.99; p  0.028). The use of GP IIb/IIIa
nhibitors was not associated with better ST-segment
esolution.
linical outcome. The one-month occurrence of re-
nfarction, re-intervention, stroke, emergency coronary ar-
ery bypass grafting, or death was similar in both groups
Table 5). In the thrombectomy group, four patients died,
ll during the in-hospital phase: one with refractory cardio-
enic shock, one secondary to electromechanical dissocia-
ion, one because of intestinal ischemia, and one because of
ree wall rupture. In the control group, four patients died,
ne because of refractory cardiogenic shock, two secondary
o free wall cardiac rupture, and one secondary to electro-
echanical dissociation. Re-infarction occurred in one pa-
ient assigned to thrombectomy and in three patients
ssigned to conventional strategy. At six months’ follow-up,
here were two additional deaths in the thrombectomy
roup, one secondary to stroke at day 35 and one during
ngiographic follow-up at five months that was complicated
able 4. Electrocardiographic Analysis
No Thrombe
T-segment elevation pre (mm) (min/max) 14.14 (0.80/55
SD 9.25
Median 11.70
T-segment elevation 1 h post (mm) (min/max) 7.15 (0.00/32
SD 6.62
Median 5.10
T-segment resolution pre–post (mm) (min/max) 6.80 (13.20
SD 9.28
Median 4.90
T-segment resolution 50%, % 52.60
T-segment resolution pre–end/ pre (min/max) 0.41 (2.00/
SD 0.49
Median 0.56
Wilcoxon rank sum test; †nonparametric repeated-measures analysis of variance (pr
able 5. Clinical Outcome at One- and Six-Month Follow-Up
MACCE Are Given in Hierarchical Order per Patient)
No
Thrombectomy Thrombectomy
p
Value
atients, n 101 100
ne month
MACCE 7 9 NS
Death 4 4 NS
Stroke 0 2 NS
Emergency CABG 0 0 NS
MI 3 1 NS
TVR 0 2 NS
ix months
MACCE 13 13 NS
Death 4 6 NS
Stroke 0 2 NS
Emergency CABG 0 0 NS
MI 4 2 NS
TVR 5 3 NS
ABG  coronary artery bypass grafting; MACCE  major adverse cardiac andh
erebrovascular events; MI  myocardial infarction; NS  not significant; TVR 
arget vessel revascularization.y pulmonary edema and shock. The six-month MACCE
ate was similar (13%) in both groups.
ISCUSSION
hrombus removal, epicardial flow, and myocardial
eperfusion. The goal of PCI for the treatment of AMI is
ot only the restoration of normal epicardial flow, which has
een shown to improve outcome (27), but also the achieve-
ent of optimal myocardial tissue reperfusion (4), which is
more reliable predictor of long-term outcomes (8,21–30).
hrombus and plaque embolization is one of the mecha-
isms affecting myocardial reperfusion by inducing mechan-
cal capillary obstruction, endothelial dysfunction, and in-
ammation (29,30) and has been shown to be associated
ith a poor long-term outcome (14).
In the present randomized study, patients undergoing
hrombectomy before coronary stenting had a lower risk of
istal embolization (2.1% vs. 10%; p  0.033) and had a
educed angiographic composite end point of slow flow, no
eflow, or distal embolization (6.0% vs. 19.8%; p  0.006).
hese traits were associated with a non-significant trend
oward improved epicardial reperfusion, as assessed by final
IMI flow grade and cTFC. The absolute ST-segment
esolution after the procedure was significantly greater in the
hrombectomy group (8.5  10.1 mm vs. 6.8  9.3 mm; p
0.003). This primary end point was chosen because it is
n easy to measure and is a reliable marker of myocardial
eperfusion and clinical outcome (21,22,28). The simpler
T-segment resolution 50% criterion (4,5,19–22,28,31)
lso was improved in the thrombectomy group (67.8% vs.
2.6%; p  0.037). Hence, it appears that effective removal
f thrombotic or soft plaque material by X-Sizer at the
esion site improves myocardial reperfusion by reducing
istal embolization during mechanical reperfusion. Further
vidence of effective thrombus removal is given by the
ignificant angiographic reduction in thrombus burden after
hrombectomy.
yocardial blush. In previous studies, myocardial blush
n Thrombectomy n p Value
98 14.35 (0.00/46.30) 96
8.72
12.70 0.6036*
96 6.33 (0.00/48.50) 94
7.68
4.20 0.1397*
0) 95 8.53 (27.90/42.37) 90
10.08 0.0331*
7.50 (0.031)†
95 67.8 90 0.0373
95 0.52 (1.35/1.00) 90
0.50
0.66 0.0296*
comparison).ctomy
.30)
.90)
/48.1
1.00)as been related to infarct size, left ventricular function (31),
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July 19, 2005:246–52 Results of the X AMINE ST Trialnd long-term mortality after AMI (8,25). In our study, the
ore laboratory evaluation did not show a significantly better
yocardial blush in patients treated with thrombectomy.
he main explanation for this is probably that in a multi-
enter and relatively small study myocardial blush is not as
owerful as ST-segment resolution as a surrogate marker.
urthermore, acquisition quality and length is crucial and
isual assessment of myocardial blush remains subjective.
linical outcome. A similar rate of MACCE at the
ix-month follow-up (13%) was found in both groups.
eath rate was relatively high compared with previous
tudies (6% in the thrombectomy group vs. 4% in the
onventional group; p  0.537), reflecting the fact that only
atients with TIMI flow grade 0 or 1 were included. It is
mportant to note that the study was not powered to
emonstrate benefits in clinical outcome.
omparison with other studies. The X-sizer was recently
valuated by Stone et al. (18) in a randomized study
nvolving 797 patients with lesions at high risk for distal
mbolization (bypass grafts or native thrombotic coronary
rteries) and, therefore, associated with a high risk of
-wave or non–Q-wave MI. This study showed a signifi-
ant reduction in the risk of extended MI (5.5 vs. 9.6; p 
.002) but did not demonstrate any clinical benefit at one
ear.
In the present study, the rate of ST-segment resolution
50% at 1 h after the procedure after adjunct thrombec-
omy was relatively high (67.8%) compared with results of
onventional balloon angioplasty initially reported by Claeys
t al. (22), who showed a ST-segment resolution 50% in
4% of cases but in a selected group of patients with better
nitial TIMI flow grade who had successful PCI (32). In a
ingle center randomized trial that included 49 patients with
T-segment elevation AMI, Beran et al. (19) reported a
ignificantly improved ST-segment resolution but no dif-
erence in myocardial blush and coronary flow reserve after
djunctive intracoronary thrombectomy with the X-Sizer
atheter compared with conventional PCI. More recently,
n a larger single-center randomized trial that included 92
atients, Napodano et al. (20) reported a better ST-segment
esolution and myocardial blush with the X-Sizer catheter.
linical follow-up was limited to one month in both
tudies.
Other mechanical approaches to reducing embolization
f thrombus during direct PCI have been used successfully.
hey include rheolytic thrombectomy (15), thrombus aspi-
ation devices (33), and distal protection devices (34). Data
rom randomized studies on the effects of these devices on
yocardial reperfusion during direct percutaneous translu-
inal coronary angioplasty have not been reported so far.
everal pharmacologic approaches to improving myocardial
eperfusion during direct angioplasty have been used. Intra-
oronary adenosine and verapamil (35,36) are administered
o reduce reperfusion injury but do not affect intracoronary
hrombus burden. The use of GP IIb/IIIa inhibitors in
atients undergoing direct PCI has been shown to improveicrovascular function by limiting the effects of embolized
hrombus and platelets and by reducing the inflammatory
esponse of the coronary microvasculature, as assessed by
oronary flow velocity (37). The combination of GP IIb/
IIa inhibitors and thrombolytic therapy showed a 59% rate
f complete ST-segment resolution (38). In the present
tudy, mechanical thrombectomy showed results that were
t least equivalent to those achieved with aggressive phar-
acologic treatment for the reduction of distal embolization
35,36). It is unlikely that the results were affected by the use
f GP IIb/IIIa inhibitors, which were administered at
imilar rate in both groups. Furthermore, multivariate anal-
sis did not identify any beneficial effect of this drug on
T-segment resolution. Similar results were found in a large
andomized trial (39) showing that the use of GP IIb/IIIa
nhibitors as an adjunct to direct PCI did not enhance
T-segment resolution or improve myocardial recovery at
even months. These data underline the importance of
echanical adjuncts for improving the outcome of direct
CI.
tudy limitations. The study reflects a multicenter expe-
ience in a limited number of patients and represents a
echanical attempt at optimizing myocardial reperfusion in
atients undergoing direct PCI. Apart from considerations
s to the safety of the X-Sizer thrombectomy device and its
ffect on myocardial reperfusion as assessed by ST-segment
esolution, no conclusions about long-term myocardial
unction and its relationship to long-term clinical follow-up
an be drawn. The study was limited to patients with
igh-risk thrombus-containing lesions with TIMI flow
rade 0 or 1 and did not include the entire AMI population,
articularly those undergoing rescue PCI after failed throm-
olysis. Another limitation of the study is that the possible
reatment benefit of adjunct pharmacologic therapy was not
valuated. Myocardial reperfusion represents such a wide
nd complex scenario that synergistic mechanical and phar-
acologic strategies may be required to preserve microvas-
ular integrity.
onclusions. Intracoronary thrombectomy with the
-Sizer catheter during catheter-based treatment of AMI
mproved myocardial reperfusion in patients presenting with
IMI flow grade 0 to 1, as assessed by a lower rate of distal
mbolization and a higher rate of ST-segment resolution.
urther clinical trials involving larger numbers of patients
re warranted to assess the impact of thrombectomy on
nfarct size as well as on clinical outcome.
eprint requests and correspondence: Dr. Thierry Lefèvre,
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